Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CIGB-210 (Center for Genetic Engineering and Biotechnology)
- Development stage
- Unknown
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intranasal, Inhalation
01
Overview
CIGB-210 is a recombinant protein therapeutic developed by the Center for Genetic Engineering and Biotechnology (CIGB) in Havana, Cuba. Originally investigated for the treatment of cystic fibrosis, it has been repurposed as a potential therapy for COVID-19. The drug is designed to inhibit the entry of the SARS-CoV-2 virus into host cells by acting as a soluble decoy or by interfering with the interaction between the viral spike protein and the host cell receptors. Clinical development in Cuba has progressed to Phase 2 trials to evaluate its safety and efficacy in patients with COVID-19.
- Other names
- keratin 10-derived peptidekeratin10-derived peptidekeratin-10-derived peptide
02
Targets
VIM (Vimentin)ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on CIGB-210 (Center for Genetic Engineering and Biotechnology).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CIGB-210 (Center for Genetic Engineering and Biotechnology).